StreetInsider.com News Articles

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), today reports on its progress during the first half of 2026.

By the end of the first half of 2026, Theraclion's commercial acceleration is beginning to show clearly across every stage of the sales cycle. This momentum has been accompanied by significant progress across all the company's strategic development areas:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion Initiates Its Commercial Momentum in the First Half of 2026

Thu, 23 Jul 2026 12:30:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Signed seven new Pay-Per-Use (PPU) contracts, with four devices made available by the end of the first half, further strengthening the

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

Wed, 15 Jul 2026 12:00:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Theraclion (Paris:ALTHE):

Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:

26,499 shares
€3,355.99

During the 1st half of 2026, a total of the following was traded:

BUY

380,553 shares

€234,517.84

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

Wed, 15 Jul 2026 12:00:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Theraclion (Paris:ALTHE):

Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:

26,499 shares
€3,355.99

During the 1st half of 2026, a total of the following was traded:

BUY

380,553 shares

€234,517.84

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

Wed, 15 Jul 2026 12:00:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Theraclion (Paris:ALTHE):

Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:

26,499 shares
€3,355.99

During the 1st half of 2026, a total of the following was traded:

BUY

380,553 shares

€234,517.84

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

Wed, 15 Jul 2026 12:00:00 -0400

MALAKOFF, France--(BUSINESS WIRE)-- Regulatory News:

Theraclion (Paris:ALTHE):

Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:

26,499 shares
€3,355.99

During the 1st half of 2026, a total of the following was traded:

BUY

380,553 shares

€234,517.84

Theraclion names Vincent Gardès as board chairman

Thu, 09 Jul 2026 02:00:28 -0400

Theraclion (Euronext Growth Paris: ALTHE), a French medical technology company, announced that its board of directors appointed Vincent Gardès as chairman, effective July 8, 2026.

Gardès succeeds Claude Lenoir, who had served as interim chairman since June 18, 2026, and who remains a director of the company. Gardès had been a director of Theraclion since the general meeting of June 18, 2026, after serving as an observer in the preceding months.

Gardès has approximately 30 years of experience in the medical device sector. He previously served as CEO of Vexim, leading the company through its acquisition by U.S. group Stryker. He subsequently

Theraclion names Vincent Gardès as board chairman

Thu, 09 Jul 2026 02:00:28 -0400

Theraclion (Euronext Growth Paris: ALTHE), a French medical technology company, announced that its board of directors appointed Vincent Gardès as chairman, effective July 8, 2026.

Gardès has approximately 30 years of experience in the medical device sector. He previously served as CEO of Vexim, leading the company through its acquisition by U.S. group Stryker. He subsequently

Theraclion names Vincent Gardès as board chairman

Thu, 09 Jul 2026 02:00:28 -0400

Theraclion (Euronext Growth Paris: ALTHE), a French medical technology company, announced that its board of directors appointed Vincent Gardès as chairman, effective July 8, 2026.

Gardès has approximately 30 years of experience in the medical device sector. He previously served as CEO of Vexim, leading the company through its acquisition by U.S. group Stryker. He subsequently

Theraclion names Vincent Gardès as board chairman

Thu, 09 Jul 2026 02:00:28 -0400

Theraclion (Euronext Growth Paris: ALTHE), a French medical technology company, announced that its board of directors appointed Vincent Gardès as chairman, effective July 8, 2026.

Gardès has approximately 30 years of experience in the medical device sector. He previously served as CEO of Vexim, leading the company through its acquisition by U.S. group Stryker. He subsequently

Theraclion names Vincent Gardès as board chairman

Thu, 09 Jul 2026 02:00:28 -0400

Theraclion (Euronext Growth Paris: ALTHE), a French medical technology company, announced that its board of directors appointed Vincent Gardès as chairman, effective July 8, 2026.

Gardès has approximately 30 years of experience in the medical device sector. He previously served as CEO of Vexim, leading the company through its acquisition by U.S. group Stryker. He subsequently